Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Study of Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection in Kidney Transplantation

NCT01630538 is registered in ClinicalTrials.gov with University of Manitoba as lead sponsor.

NCT NCT01630538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01630538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Study of Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection in Kidney Transplantation
Lead sponsor
University of Manitoba
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2013
Completion date
January 18, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody mediated rejection